Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares the biggest updates in myeloproliferative neoplasms (MPNs) from this year's ASH. These include research on CALR variant allele frequency (VAF) dynamics, findings from the FREEDOM2 study (NCT03952039), the use of fedratinib in low platelet patients, and rethinking the risk stratification of polycythemia vera. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть